Lv11
70 积分 2022-11-02 加入
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America
19分钟前
求助中
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
9天前
已完结
Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
1个月前
已关闭
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
Imlunestrant (Inluriyo) for Advanced Breast Cancer
1个月前
已关闭
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial
1个月前
已完结
Advancing neoadjuvant therapy with inetetamab for HER2-Positive breast cancer
1个月前
已完结
HER2-positive metastatic breast cancer: a comprehensive review
1个月前
已关闭
Global, Regional, and National Burden of Breast Cancer Among Females, 1990–2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023
1个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
1个月前
已完结
皖公网安备34019202002308
